Dexin Kong, Ph.D.
Dexin Kong, PhD
Professor
Chair
Department of Clinical Pharmacy
Tianjin Medical University
22 Qixiangtai Road
Tianjin 300070
Phone: +86-22-83336673
Email: kongdexin@tmu.edu.cn
Education
Bachelor Shandong University, Jinan, China, 1991
Master Shandong University, Jinan, China, 1994
Ph.D. Osaka University, Osaka, Japan, 2005
Professional Experience
2010- Professor, Department of Clinical Pharmacy, Tianjin Medical University, Tianjin, China
2006-2010 Senior scientist, Department of Molecular Pharmacology, JFCR, Tokyo, Japan
2005-2006 Research associate, School of Pharmacy, CUHK, Hong Kong SAR, China
1996-2000 Instructor, School of Life Sciences, Shandong University, Jinan, China
1994-1996 Assistant professor, School of Life Sciences, Shandong University, Jinan, China
Honors
1. 2012.01, Invitation fellowship (short term), JSPS
2. 2012.09, Awarded the title of “Distinguished Professor of Tianjin”
3. 2013.05,Bridge fellowship, JSPS
4. 2019. 05, Bridge fellowship, JSPS
5. 2020. 01, Leading scientist in Pharmaceutical Sciences of Tianjin,
6. 2020.11, Chief, Innovative talent team in Molecular targeted drug research of Tianjin
Professional Service
Editorial Board
Frontiers in Pharmacology
Frontiers in Oncology
Journal of Cancer
Biochemistry & Pharmacology
E-journal of Chemistry
OA Cancer
Reviewer for:
European Journal of Cancer
Acta Pharmaceutica Sinica B
International Journal of Cancer
British Journal of Pharmacology
European Journal of Pharmacology
Current Medicinal Chemistry
Biomedicine and Pharmcotherapy
International Journal of Biological Sciences
Molecules
Phytochemistry letters
International Journal of Nanomedicine
Bioscience Reports
Food and Function
Cancer medicine
Academic conference chair
Chemotherapeutic Drug Discovery: Cancer Pharmacology Research Conference(New York, 2017)
Innovative drug discovery and development in the context of precision medicine (Tianjin, 2018)
Membership of Academic Society
American Association for Cancer Research (AACR)
Japanese Cancer Association (JCA)
Chinese Pharmacological Society (CPS)
Books
Chemotherapy-Sensitizing Agents for Cancer (English), Editorial Board, 2019, Elsevier.
Publication (selected)
1) Peng X, Zhang S, Jiao W, Zhong Z, Yang Y, Claret FX, Elkabets M, Wang F, Wang R, Zhong Y, ChenZS, Kong D. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021, in press.
2) Zhang Z, Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Liu R, Wang W, Du B*, Zhong Y*, Kong D*. Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo. Chem Eng J. 2021; 406: 126801.
3) Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R*, Zhong Y*, Kong D*. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021; 12(6):546.
4) Zhao X, Zhang N, Huang Y, Dou X, Peng X, Wang W, Zhang Z, Wang R, Qiu Y, Jin M, Kong D. Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo. Front Cell Dev Biol. 2021 Apr 20; 9: 655559.
5) Shunli Pan, Xiaoxia Zhao, Chen Shao, Bingjie Fu, Yingying Huang, Ning Zhang, Xiaojing Dou, Zhe Zhang, Yuling Qiu, Ran Wang, Meihua Jin, Kong D*. STIM1 promotes angiogenesis by reducing exosomal miR-145 in breast cancer MDA-MB-231 cells. Cell Death Dis. 2021, 12: 38.
6) Shao C, Huang Y, Fu B, Pan S, Zhao X, Zhang N, Wang W, Zhang Z, Qiu Y, Wang R, Jin M, Kong D. Targeting c-Jun in A549 Cancer Cells Exhibits Antiangiogenic Activity In Vitro and In Vivo Through Exosome/miRNA-494-3p/PTEN Signal Pathway. Front Oncol. 2021 Apr 9;11:663183.
7) Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells. Recent Pat Anticancer Drug Discov. 2021. doi: 10.2174/1574892816666210224155403.
8) Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, Wang W, Lin P, Zhang Z, Zhong Y, Kong D*. Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. Front Pharmacol. 2020, 11:186.
9) Hou Y-Q , Ying-Ying Wang, Xing-Can Wang, Yao Liu, Chun-Ze Zhang, Zhe-Sheng Chen, Zhe Zhang, Wei Wang, Kong D*. Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells in vitro. Gastroenterol Rep. 2020, 8: 465-475.
10) Zhang L, Chen T, Dou Y, Zhang S, Liu H, Khishignyam T, Li X, Zuo D, Zhang Z, Jin M, Wang R, Qiu Y, Zhong Y, Kong D*. Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells. Front. Oncol. 2019;9:1032.
11) Peng X, Liu Y, Zhu S, Peng X, Li H, Jiao W, Lin P, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2019;145: 2921-2936.
12) Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D*. Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Front Oncol. 2019, 9:514.
13) Pan S, Zhao X, Ji N, Shao C, Fu B, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Inhibitory effect of taxifolin on mast cell activation and mast cell-mediated allergic inflammatory response. Int Immunopharmacol. 2019, 71:205-214.
14) Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D*, Chen ZS. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 2019, 440-441:82-93.
15）Zhang Z, Liu J, Wang Y, Tan X, Zhao W, Xing X, Qiu Y, Wang R, Jin M, Fan G, Zhang P, Zhong Y, Kong D*. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells. FASEB J. 2018, 32: 5967-5975.
16) Wang Z, Wang Y, Zhu S, Liu Y, Peng X, Zhang S, Zhang Z, Qiu Y, Jin M, Wang R, Zhong Y, Kong D*. DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway. Front Pharmacol. 2018, 9:1450.
17) Ji N, Yang Y, Lei ZN, Cai CY, Wang JQ, Gupta P, Xian X, Yang DH, Kong D*, Chen ZS. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochem Pharmacol. 2018, 158:274-285.
18) Ji N, Pan S, Shao C, Chen Y, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Spinacetin Suppresses the Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mouse Model. Front Pharmacol. 2018, 9:824.
19) Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Teng QX, Chen ZS, Kong D*, Yang DH. VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. Front Pharmacol. 2018, 30,9:1236.
20) Liu J, Tan X, Zhao W, Liu J, Xing X, Fan G, Zhang P, Zhang Z, Zhong Y*, Kong D*. In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells. Curr Cancer Drug Targets. 2018, 18:1-9.
21) Shao C, Fu B, Ji N, Pan S, Zhao X, Zhang Z, Qiu Y, Wang R, Jin M, Wen K, Kong D*. Alisol B 23-Acetate Inhibits IgE/Ag-Mediated Mast Cell Activation and Allergic Reaction. Int J Mol Sci. 2018，19(12). pii: E4092.
22) Chen X, Guo Y, Han R, Liu H, Ding Y, Shi Y, Kong D, Ma X. Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1/Th17 cells and reducing the production of proinflammatory cytokines. Cell Immunol. 2018, 329:41-49.
23) Peng X, Liu Y, Peng X, Wang Z, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Clinical features and the molecular biomarkers of olfactory neuroblastoma. Pathol Res Pract. 2018, 214:1123-1129.
24) Peng X, Wang Z, Liu Y, Peng X, Liu Y, Zhu S, Zhang Z, Qiu Y, Jin M, Wang R, Zhang Q, Kong D*. Oxyfadichalcone C inhibits melanoma A375 cell proliferation and metastasis via suppressing PI3K/Akt and MAPK/ERK pathways. Life Sci. 2018;206:35-44.
25) Zhang L, Wang Z, Khishignyam T, Chen T, Zhou C, Zhang Z, Jin M, Wang R, Qiu Y, Kong D*. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells. Biomed Pharmacother. 2018;103:1069-1078.
26) Chen X, Han R, Hao P, Wang L, Liu M, Jin M, Kong D, Li X. Nepetin inhibits IL-1β induced inflammation via NF-κB and MAPKs signaling pathways in ARPE-19 cells. Biomed Pharmacother. 2018; 101:87-93.
27) Li Y, Cui T, Kong X, Yi X, Kong D, Zhang J, Liu C, Gong M. Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability. FASEB J. 2018, 32:2992-3004.
28) Liu Y, Zhang X, Kelsang N, Tu G, Kong D, Lu J, Zhang Y, Liang H, Tu P, Zhang Q. Structurally Diverse Cytotoxic Dimeric Chalcones from Oxytropis chiliophylla. J Nat Prod. 2018; 81(2):307-315.
29) Peng X, Zhou C, Hou X, Liu Y, Wang Z, Peng X, Zhang, Wang R, Kong D*. Molecular characterization and bioactivity evaluation of two novel bombinin peptides from the skin secretion of Oriental fire-bellied toad, Bombina orientalis. Amino Acids. 2018; 50(2):241-253
30) Zhou C, Wang Z, Peng X, Liu Y, Lin Y, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Discovery of two Bombinin peptides with antimicrobial and anticancer activities from the skin secretion of Oriental Fire‐bellied toad, Bombina orientalis. Chemical Biology & Drug Design, 2018; 91(1):50-61.
31) Chen Y, Ji N, Pan S, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells. Inflammation, 2017, 40(6):1959-1966.
32) Chen X, Ji N, Qin N, Tang SA, Wang R, Qiu Y, Duan H, Kong D, Jin M. 4.1,6-O,O-Diacetylbritannilactone Inhibits Eotaxin-1 and ALOX15 Expression Through Inactivation of STAT6 in A549 Cells. Inflammation, 2017, 40(6):1967-1974.
33) Jin M, Kim S, Qin N, Chen X, Ji N, Tang SA, Kong D, Lee E, Duan H. 1,3.1,6-O,O-Diacetylbritannilactone suppresses activation of mast cell and airway hyper-responsiveness. Immunopharmacol Immunotoxicol, 2017, 39(4):173-179.
34) Zhou Q, Chen Y, Zhang L, Zhong Y, Zhang Z, Wang R, Jin M, Gong M, Qiu Y, Kong D*. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. Oncotarget, 2017, 8(24):39064-39076.
35) Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y, Kong D*. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget, 2017, 8(17): 28906-28921.
36) Wang R, Zhang Q , Peng X, Zhou C, Zhong Y, Chen X, Qiu Y, Jin M, Gong M, Kong D*. Stellettin B induces G1 arrest, apoptosis and autophagy in human Non-small cell lung cancer A549 Cells via blocking PI3K/Akt/mTOR pathway. Sci Rep, 2016，6: 27071.
37) Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D*. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget, 2016, 7 (15): 19897-19909.
38) Huang C, Yi X, Kong D, Chen L, Gong M. Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide. Oncotarget. 2016, 7(32): 52230-52238.
39) Chen Y, Zhou Q, Zhang L, Wang R, Jin M, Qiu Y, Kong D*. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Oncol Rep. 2016, 2016, 36: 3543-3650.
40) Wang P, He Y, Li D, Han R, Liu G, Kong D, Hao J. Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury. J Neuroinflammation. 2016, 13(1):192.
41) Zhao W, Qiu Y, Kong D*. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharmaceutica Sinica B, 2016, 7(1):27-37.
42) Zhou Q, Chen Y, Chen X, Zhao W, Zhong Y, Wang R, Jin M, Qiu Y, Kong D*. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells. Int J Biol Sci. 2016, 12(6): 631-8.
43) Xu J, Gao C, Zhang F, Ma X, Peng X, Zhang R, Kong D, Simard AR, Hao J. Differentially expressed lncRNAs and mRNAs identified by microarray analysis in GBS patients vs healthy controls. Sci Rep, 2016，6: 21819.
44) Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M*. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep, 2015; 5:18039.
45) Zhang F, Gao C, Ma X, Peng X, Zhang R, Kong D, Simard AR, Hao J*. Expression Profile of Long Noncoding RNAs in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients. CNS Neurosci Ther, 2016, (4):298-305
46) Chen X, Xu H, Li B, Wang F, Chen X, Kong D, Lin X*. Preparation and Antitumor Activity of CS5931, A Novel Polypeptide from Sea Squirt Ciona Savignyi. Mar Drugs, 2016, 14: pii: E47.
47) Tang SA, Zhou Q, Guo W, Qiu Y, Wang R, Jin M, Zhang W, Li K, Yamori T, Dan S, Kong D*. In vitro Antitumor Activity of Stellettin B, a Triterpene from Marine Sponge Jaspis stellifera, on Human Glioblastoma Cancer SF295 Cells. Mar Drugs. 2014, 12: 4200-4213.
48) Chen X, Tang SA, Lee E, Qiu Y, Wang R, Duan HQ, Dan S, Jin M, Kong D*. IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-κB and MAPK inactivation in RAW264.7 cells. Life Sci, 2015; 124:8-15.
49) Wang X, Tang SA, Wang R, Qiu Y, Jin M, Kong D*. Inhibitory effects of JEUD-38, a new sesquiterpene lactone from Inula Japonica Thunb, on LPS-induced iNOS expression in RAW264.7 cells. Inflammation, 2015; 38(3):941-8.
50) Kong D*, Yamori T, Yamazaki K, Dan S*. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs, 2014, 32: 1134-1143.
51) Jin M, Zhou Q, Lee E, Dan S, Duan HQ, Kong D*. AS252424, a PI3K Inhibitor, Downregulates Inflammatory Responsiveness in Mouse Bone Marrow-Derived Mast Cells. Inflammation, 2014, 37 (4): 1254-1260.
52）Zhao W, Guo W, Zhou Q, Ma S, Wang R, Qiu Y, Jin M, Duan HQ, Kong D*. In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells. Int. J. Mol. Sci. 2013, 14, 13577-13591.
53) Kong D, Yamori T*. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 2012, 20 (6): 1947-1951.
54) Kong D, Dan S, Yamazaki K, Yamori T*. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur. J. Cancer. 2010, 46 (6): 1111-1121.
55) Kong D, Okamura M, Yoshimi H, Yamori T*. Anti-angiogenic effect of a novel phosphatidylinositol 3-kinase inhibitor, ZSTK474. Eur. J. Cancer. 2009, 45 (3): 857-865. cover paper.
56) Jin M, Zhao W, Zhang Y, Kobayashi M, Duan H, Kong D*. Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 cells. Int. J. Mol. Sci. 2011, 12 (11): 7352-7359.
57) Kong D*, Zhang Y, Yamori T, Duan H, Jin M. Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms. Molecules. 2011, 16 (6): 5159-67.
58) Kong D*, Yamori T, Kobayashi M, Duan H. Antiproliferative and antiangiogenic activities of Smenospongine, a marine sponge Sesquiterpene Aminoquinone. Mar. Drugs. 2011, 9 (2): 154-161.
59) Kong D, Yamori T*. Advances in development of Phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem. 2009, 16 (22): 2839-2854.
60) Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M*. Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar. Drugs 2008, 6 (3): 480-488.
61) Kong D, Yamori T*. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008, 99 (9): 1734-1740.
62) Kong D, Yamori T*. ZSTK474 is an ATP-competitive inhibitor of class I PI3 kinase isoforms. Cancer Sci. 2007, 98 (10): 1638-1642.
63) Kong D*. PI3K inhibitors: novel molecular-targeted drug candidates for cancer therapy. Biochem. Pharmacol. 2012, 1 (6): e126.
64) Kong D, Yamazaki K, Yamori T*. Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the SCADS library. Biol. Pharm. Bull. 2010, 33 (9): 1600-1604.
65) Kong D, Yamori T*. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified by JFCR39 drug discovery system. Acta Pharmacol. Sin. 2010, 31 (9): 1189-1197.
66) Kong D, Yaguchi S, Yamori T*. Effect of ZSTK474, a Novel Phosphatidylinositol 3-kinase Inhibitor, on DNA-Dependent Protein Kinase. Biol. Pharm. Bull; 2009, 32 (2): 297-300.
Grant
Ongoing:
1. Antitumor effect of STELB in combination with Temozolimide or Olaparib via inhibiting homologous recombination repair，NSFC, 2021.01-2024.12.
2. Nanoparticle-mediated delivery of a new PI3K inhibitor to enhance immunotherapy
efficacy in PIK3CA-mutated head and neck cancer，2020.10-2023.09.
Completed:
1. Anti-metastatic effect of PI3K inhibitors on prostate cancer. Tianjin Natural Science Foundation. 2014.04-2016.03.
2. Anti-metastatic effect on prostate cancer by targeting PI3K isoforms with low molecular probes. NSFC, 2014.01-2017.12.
3. Innovative drug discovery and development in the context of precision medicine. NSFC, 2018.09-2018.12.31
4. Antitumor effect of STELB on glioblastoma and the related mechanism，NSFC, 2017.01-2020.12.
5. Establishment of an antitumor drug discovery system-KTC21. Major project of Tianjin for new drug development，2017.10-2020.09.
